UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 5,266 Shares of RxSight, Inc. (NASDAQ:RXST)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 8.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 68,818 shares of the company’s stock after purchasing an additional 5,266 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in RxSight were worth $3,402,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Brown Capital Management LLC bought a new position in shares of RxSight in the third quarter valued at approximately $26,813,000. Marshall Wace LLP purchased a new position in RxSight in the second quarter worth $19,512,000. Driehaus Capital Management LLC increased its position in shares of RxSight by 74.9% during the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after purchasing an additional 302,367 shares during the last quarter. Baillie Gifford & Co. increased its position in shares of RxSight by 438.8% during the 2nd quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock valued at $21,554,000 after purchasing an additional 291,733 shares during the last quarter. Finally, William Blair Investment Management LLC bought a new stake in shares of RxSight during the 2nd quarter worth $14,942,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on RXST shares. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $42.00 price target (down previously from $56.00) on shares of RxSight in a research report on Wednesday. Jefferies Financial Group began coverage on RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price objective for the company. Finally, UBS Group began coverage on shares of RxSight in a report on Friday, December 6th. They set a “buy” rating and a $52.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $62.13.

RxSight Stock Up 3.9 %

NASDAQ:RXST opened at $37.30 on Friday. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -44.94 and a beta of 1.11. The company’s 50 day moving average price is $46.98 and its 200-day moving average price is $50.86. RxSight, Inc. has a 52 week low of $34.92 and a 52 week high of $66.54.

Insider Activity

In related news, Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total transaction of $173,518.16. Following the sale, the director now owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ilya Goldshleger sold 3,105 shares of RxSight stock in a transaction on Friday, November 29th. The shares were sold at an average price of $46.08, for a total transaction of $143,078.40. Following the completion of the sale, the insider now owns 42,246 shares in the company, valued at approximately $1,946,695.68. This represents a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,807 shares of company stock valued at $3,202,275 in the last ninety days. 9.36% of the stock is currently owned by company insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.